source
- Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approvalNew Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…
- Cadrenal Therapeutics launches strategic review to explore sale or partnership for its late-stage cardiology pipelineCadrenal Therapeutics, a heart-focused biotech, announced a strategic review of its late-stage cardiology pipeline, seeking to offload assets or the entire company. The board is evaluating options…Fierce Biotech · 1mo agoDealNegative